NEW YORK (GenomeWeb News) - UK cancer detection firm Oncimmune will develop a diagnostic test for lung cancer using Proteome Sciences’ patents covering the Annexin I and Annexin 2 proteins under a non-exclusive licensing agreement announced by the two firms this week.
 
A test is expected to hit the market during the first half of the year, Proteome Sciences said in a statement. It will receive royalty payments from product sales under the agreement.
 
Further terms of the deal were not disclosed.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.